REGENXBIO (NASDAQ:RGNX) Upgraded at StockNews.com

StockNews.com upgraded shares of REGENXBIO (NASDAQ:RGNX) from a sell rating to a hold rating in a research report released on Friday.

Other equities analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of REGENXBIO in a report on Wednesday, January 15th. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday, November 20th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Finally, Raymond James started coverage on REGENXBIO in a research note on Friday. They issued an “outperform” rating and a $27.00 price objective for the company. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.64.

REGENXBIO Stock Down 2.6 %

Shares of NASDAQ RGNX opened at $8.21 on Friday. REGENXBIO has a twelve month low of $6.56 and a twelve month high of $28.80. The firm has a market cap of $406.72 million, a P/E ratio of -1.63 and a beta of 1.29. The company has a 50 day moving average of $8.08 and a 200 day moving average of $10.02.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the period. FMR LLC boosted its holdings in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC boosted its holdings in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 3,720 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of REGENXBIO during the 3rd quarter valued at about $140,000. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.